Correlation between molecular markers and clinical pathology in colorectal cancer

Abstract

<p class="MsoNormal" style="text-align: justify;"><span style="font-family: Times New Roman;">Immunohistochemical detection of colorectal cancer (CRC) plays a key role in guiding targeted therapy and assessing clinicopathological characteristics.This review focuses on the key immunohistochemical markers such as HER2, KRAS, NRAS, BRAF and PD-L1, and discusses the selection of targeted therapy drugs and the clinicopathological relationship.The overexpression of HER2 is associated with the invasion, metastasis and poor prognosis of CRC.Her2-targeted drugs such as trastuzumab provide a new way for the treatment.KRAS, NRAS, and BRAF mutations are similarly associated with a poor prognosis in CRC, but currently targeted agents targeting these mutations have had limited efficacy.As an immune checkpoint molecule, the high expression of PD-L1 is related to the immune response and prognosis of CRC.PD-L1 inhibitors have become an important tool for immunotherapy.Through the detection of these indicators, doctors can more accurately evaluate the tumor characteristics and prognosis of CRC patients, and formulate personalized treatment plans for patients.These immunohistochemical markers not only provide a basis for targeted therapy of CRC, but also deepen our understanding of the clinicopathological characteristics of CRC.</span></p>